SEC Filing | Akebia Therapeutics

View:

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rucci Carolyn M.

(Last)

(First)

(Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST ST.

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
	Officer (give title below)	Other (specify below)
SVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/02/2026		S		16,846⁽¹⁾⁽²⁾	D	$1.39	641,304	D
Common Stock	02/02/2026		S		25,382⁽¹⁾⁽³⁾	D	$1.39	615,922	D
Common Stock	02/02/2026		S		27,544⁽¹⁾⁽⁴⁾	D	$1.39	588,378	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.

3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.

4. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

Remarks:

	/s/ John P. Butler, attorney-in-fact for Carolyn M. Rucci	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby makes, constitutes and appoints each of John P.
Butler, Erik J. Ostrowski and Richard C. Malabre, or either of them acting
singly, and with full power of substitution, re-substitution and delegation,
the undersigneds true and lawful attorney in fact (each of such persons and
their substitutes and delegees being referred to herein as the
Attorney-in-Fact), with full power to act for the undersigned and in the
undersigneds name, place and stead, in the undersigneds capacity as an officer,
director or stockholder of Akebia Therapeutics, Inc. (the Company), to:

(1) Take such actions as may be necessary or appropriate to enable the
undersigned to submit and file forms, schedules and other documents with
the U.S. Securities and Exchange Commission (SEC) utilizing the SECs Electronic
Data Gathering and Retrieval (EDGAR) system, which actions may include
(a) enrolling the undersigned in EDGAR Next and (b) preparing, executing and
submitting to the SEC a Form ID, amendments thereto, and such other documents
and information as may be necessary or appropriate to obtain and/or modify codes
and passwords enabling the undersigned to make filings and submissions utilizing
the EDGAR system;

(2) Prepare and execute any and all forms, schedules and other documents
(including any amendments thereto) the undersigned is required to file with the
SEC, or which the Attorney-in-Fact considers it advisable for the undersigned to
file with the SEC, under Section 13 or Section 16 of the Securities Exchange Act
of 1934 or any rule or regulation thereunder, or under Rule 144 under the
Securities Act of 1933 (Rule 144), including Forms 3, 4 and 5, Schedules 13D and
13G, and Forms 144 (all such forms, schedules and other documents being referred
to herein as (SEC Filings);

(3) Submit and file SEC Filings with the SEC utilizing the EDGAR system or any
such third-party system with which the Company, the undersigned or the
Attorney-in-Fact uses to make EDGAR filings with the SEC or cause them to be
submitted and filed by a person appointed under Section 5 below;

(4) File, submit or otherwise deliver SEC Filings to any securities exchange on
which the Companys securities may be listed or traded;

(5) Act as an account administrator for the undersigneds EDGAR account,
including:
(i) appoint, remove and replace account administrators, account users, technical
administrators and delegated entities; (ii) maintain the security of the
undersigneds EDGAR account, including modification of access codes;
(iii) maintain, modify and certify the accuracy of information on the
undersigneds EDGAR account dashboard; (iv) act as the EDGAR point of contact
with respect to the undersigneds EDGAR account; and (v) any other actions
contemplated by Rule 10 of Regulation S-T with respect to account
administrators; or act as a delegated administrator for the undersigneds EDGAR
account, including: (i) appoint, remove and replace delegated account
administrators and users; (ii) maintain the security of the undersigneds
EDGAR account; and (iii) any other actions contemplated by Rule 10 of
Regulation S-T with respect to delegated entities;

(6) Cause the Company to accept a delegation of authority from any of the
undersigneds EDGAR account administrators and, pursuant to that delegation,
authorize the CompanysEDGAR account administrators to appoint, remove or
replace users for the undersignedsEDGAR account; and

(7) Obtain, as the undersigneds representative and on the undersigneds behalf,
information regarding transactions in the Companys equity securities from any
third party, including the Company and any brokers, dealers, employee benefit
plan administrators and trustees, and the undersigned hereby authorizes any
such third party to release any such information to the Attorney-in-Fact.

The undersigned acknowledges that:
a) This Power of Attorney authorizes, but does not require, the Attorney-in-Fact
to act in his or her discretion on information provided to such Attorney-in-Fact
without independent verification of such information;
b) Any documents prepared or executed by the Attorney-in-Fact on behalf of the
undersigned pursuant to this Power of Attorney will be in such form and will
contain such information as the Attorney-in-Fact, in his or her discretion,
deems necessary or desirable;
c) Neither the Company nor the Attorney-in-Fact assumes any liability for the
undersigneds responsibility to comply with the requirements of Section 13 or
Section 16of the Exchange Act or Rule 144, any liability of the undersigned for
any failure to comply with such requirements, or any liability of the
undersigned for disgorgement of profits under Section 16(b) of the Exchange Act;
and
d) This Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigneds obligations under Section 13 or Section 16
of the Exchange Act, including, without limitation, the reporting requirements
under Section 13 or Section 16 of the Exchange Act.

The undersigned hereby grants to the Attorney-in-Fact full power and authority
to do and perform each and every act and thing requisite, necessary or advisable
to be done in connection with the foregoing, as fully, to all intents and
purposes, as the undersigned might or could do in person, hereby ratifying and
confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Power
of Attorney.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G
or Forms 144 with respect to the undersigneds holdings of and transactions in
securities of the Company, unless earlier revoked by the undersigned in a
signed writing delivered to the Attorney-in-Fact. This Power of Attorney
revokesall previous powers of attorney with respect to the subject matter
of this Power of Attorney.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of
February 3, 2026.



By:
/s/ Carolyn M. Rucci
Name:
 Carolyn M. Rucci